ARA-290 – 10mg

ARA-290 Overview

ARA-290, also known as cibinetide, is a synthetic peptide derived from the beta-helix region of erythropoietin (EPO). Designed to explore EPO’s tissue-protective signaling without stimulating red blood cell production, ARA-290 has attracted research interest for its potential roles in cellular protection and neuronal function. Studies have investigated its interaction with receptors involved in cellular stress responses, with a focus on inflammatory signaling, vascular stability, and tissue repair.

ARA-290 Studies and Research Data

Immune Modulation

ARA-290 has been studied for its potential to influence immune signaling through tissue-protective receptors expressed on cells such as macrophages and dendritic cells. Experimental findings suggest that this interaction may help regulate pro-inflammatory cytokine release and shape downstream immune responses. In preclinical models of systemic lupus erythematosus (SLE) and colitis, researchers have explored its effects on autoantibody activity and inflammatory pathways, supporting continued investigation into its role in immune regulation.

Pain Signaling Pathways

Research into ARA-290 and neuropathic pain has focused on the innate repair receptor (IRR) and its role in sensory signaling. Preclinical studies have also examined potential effects on TRPV1, a receptor involved in detecting painful stimuli. Findings from mouse models suggest that ARA-290 may influence calcium responses in sensory neurons and modify pain-related behaviors, making these pathways an area of ongoing research.

Vascular and Retinal Repair

ARA-290 has been investigated in models of retinal ischemia for its potential to support endothelial colony-forming cells (ECFCs), which contribute to vascular repair. In oxygen-induced retinopathy models, treatment was associated with changes in inflammatory cytokines and improvements in structural markers of vascular regeneration. These findings suggest a possible role in pathways involved in vascular stability and retinal tissue repair.

Inflammatory Cytokine Regulation

Studies in mouse models of islet transplantation have explored whether ARA-290 can regulate macrophage activity and limit inflammatory cytokines, including TNF-α, IL-6, and IL-12. Preliminary findings suggest that it may help protect islet cells under inflammatory stress. Proposed mechanisms involve the EPOR-βcR receptor complex and downstream PI3K-Akt and JAK2-STAT5 signaling pathways, which are associated with cell survival and the regulation of apoptosis.

Research Outlook

ARA-290 research spans immune modulation, inflammatory signaling, vascular repair, and pain-related pathways. Preclinical findings provide a basis for further investigation, but additional studies are needed to establish its mechanisms, assess safety, and determine whether these effects translate into clinical benefit.

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception